-A +A


LBDA is pleased to offer the following articles on LBD-related research, written for the general public.

1/20/2012 - New guidelines on diagnosing Alzheimer's will also improve the rate of detection of Lewy bodies and changes of other neurodegenerative disease at autopsy.

06/29/2011 - GE Healthcare announced recently the availability of DaTscan™ (Ioflupane I 123 Injection), in more than 80 hospitals across the US. DaTscan is the first FDA-approved radiopharmaceutical adjunct imaging agent to help physicians evaluate patients with suspected parkinsonian syndromes, such as Parkinson's disease (PD). 

05/11/2011 - Scientists studying alpha-synuclein, the protein involved in Lewy body dementia and Parkinson’s disease, have found that in its natural, healthy state the protein has a radically different structure than previously thought.

03/16/2011 - Do you know the difference between a CT scan, an MRI, or SPECT or PET scans? LBDA has put together a helpful overview on the different types of brain imaging and how they help differentiate between forms of dementia.

01/31/2011 - The FDA approves the first diagnostic imaging agent to aid in the diagnosis of progressive movement disorders.

01/24/2011 - A recently published research paper by the European Journal of Neurology indicates that the presence of adult ADHD symptoms poses a 3-fold risk of developing DLB, but the LBDA Scientific Advisory Council has expressed concern that the conclusions drawn are premature.

10/13/2010 - The Michael J. Fox Foundation recently launched the Parkinson’s Progression Markers Initiative (PPMI), a landmark clinical study to identify and validate Parkinson’s disease biomarkers.

10/08/2010 - ADNI GO, a landmark research study sponsored by the National Institute on Aging (NIA) at the National Institutes of Health (NIH), is examining the sequence and timing of events at the initial onset of mild cognitive symptoms.

09/15/2010 - Differential diagnosis is possible by comparing amyloid-beta42 and alpha-synuclein protein levels in cerebrospinal fluid.

09/06/2010 - A recent study provides more evidence that patients with dementia with Lewy bodies (DLB) may benefit from memantine.